Each medical therapeutic option is associated with a specific group of adverse events, dopamine agonists with dizziness, gastrointestinal discomfort, and hypotension; GH receptor agonists with gastrointestinal discomfort, skin reactions, and abnormal liver enzymes; and somatostatin analogs with abdominal pain, diarrhea, and cholelithiasis [64, 65]. The gene discussed is GHR; the disease is cholelithiasis.